RT Journal Article
SR Electronic
T1 Oral Azelaic Acid Ester Decreases Markers of Insulin Resistance in Overweight Human Male Subjects
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1173
OP 1186
DO 10.21873/invivo.11890
VO 34
IS 3
A1 ROBERT T. STREEPER
A1 CHRISTOPHER LOUDEN
A1 ELZBIETA IZBICKA
YR 2020
UL http://iv.iiarjournals.org/content/34/3/1173.abstract
AB Background/Aim: Insulin resistance (IR) is linked to increased risk of cardiovascular disease and cancer. We examined safety and efficacy of the natural product diethyl azelate (DEA) in overweight males with a varying degree of IR. Patients and Methods: Seventeen subjects [age 18-42, hemoglobin A1c (A1c) of 5.2-6.2%] received orally 1 mg/kg DEA daily for 21 days. Blood plasma glucose, insulin and lipid levels were assessed before and after treatment. Results: DEA was well tolerated without hypoglycemia or adverse effects except transient diarrhea (n=1). DEA significantly reduced fasting glucose by 6.06 mg/dl (n=8) and insulin by 37.8% (n=8) in subjects with IR and/or A1c ≥5.6%. Furthermore, it improved cholesterol/HDL, LDL/HDL, and non-cholesterol HDL/HDL by 5.4, 6.5, and 6.6%, respectively in all subjects, and by 8.0, 9.8, and 9.8%, respectively in 9 subjects with A1c ≥5.6%. Conclusion: DEA efficacy correlates with the degree of IR. DEA holds promise as a novel treatment for the management of IR.